18:44 , Mar 23, 2018 |  BC Week In Review  |  Financial News

Beacon launches biotech incubator

Life science and real estate investment firm Beacon Capital (New York, N.Y.) launched a $30-$50 million incubator fund for life science startups in New York and New Jersey. The incubator, Beacon Pharma, will provide $30,000...
23:10 , Mar 20, 2018 |  BC Extra  |  Financial News

Beacon launches NY/NJ biotech incubator

Life science and real estate investment firm Beacon Capital launched a $30-$50 million incubator fund for life science startups in New York and New Jersey. The incubator, Beacon Pharma, will provide $30,000 to $1 million...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Company News

Alliance Pharma, Beacon Pharma sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary acquired marketing rights in the U.K. to six dermatology products from Beacon for £2.4 million ($3.8 million) in cash. Alliance said the products, which include five prescription brands and one...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Clinical News

DigiFab regulatory update

Swissmedic approved DigiFab to treat digoxin toxicity. The polyclonal antibody against digoxin (digitalis) glycosides is also approved in the U.S. and is under review in the U.K. and Canada. Beacon Pharmaceuticals Ltd. (Tunbridge Wells, U.K.)...
08:00 , Jan 15, 2007 |  BC Week In Review  |  Clinical News

DigiFab regulatory update

Protherics submitted a regulatory application to Health Canada for DigiFab to treat digoxin toxicity. The company expects marketing approval next year for the formulation of anti-digoxin polyclonal antibody fragments. DigiFab is approved in the U.S....
08:00 , Dec 4, 2006 |  BC Week In Review  |  Company News

Protherics, Roche sales and marketing update

ROCZ granted PTI rights to market Digitalis Antidot, which is approved in France, Germany and Switzerland to treat digoxin toxicity. PTI intends to replace it with PTI's own digoxin antidote DigiFab in early 2007. PTI...
07:00 , Sep 6, 2004 |  BC Week In Review  |  Clinical News

DigiFAb regulatory update

PTI submitted an MAA to the U.K.'s Medicines and Healthcare Products Regulatory Agency for DigiFab to treat digoxin toxicity. The formulation of anti-digoxin polyclonal antibody fragments is approved in the U.S. for the same indication....
07:00 , Oct 14, 2002 |  BC Week In Review  |  Company News

Questcor, Beacon Pharma sales and marketing update

Beacon will exclusively market in the U.K. QSC's H.P. Acthar gel to treat infantile spasm, or West syndrome. Questcor Pharmaceuticals Inc. (QSC), Union City, Calif.   Beacon Pharmaceuticals Ltd. , Kent, U.K.   Business: Infectious...